Skip to content

Clinical efficacy of integrated traditional Chinese and western medicine in the treatment of asymptomatic hyperuricemia

Clinical efficacy of integrated traditional Chinese and western medicine in the treatment of asymptomatic hyperuricemia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000473
Enrollment
Unknown
Registered
2024-09-25
Start date
2024-10-01
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia

Interventions

Traditional Chinese medicine group:Jianpi Huashui Xizhuo Decoction (1 dose daily take warm half an hour after breakfast and dinner)
Integrated traditional Chinese and western medicine group:Jianpi-huashi-xiezhuo Decoction (1 dose daily warm take half an hour after breakfast and dinner) + allopurinol tablets (0.1g qd)
Western medicine group:Allopurinol tablets (0.1g qd)

Sponsors

The Third People's Hospital affiliated to Fujian University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) It met the diagnostic criteria of HUA and did not cause joint inflammation. 2) meeting the diagnostic criteria of spleen deficiency and dampness; 3) patients with hypertension abnormal lipid metabolism diabetes obesity coronary heart disease and other comorbidities and serum uric acid level =480µmol/L or patients with serum uric acid level =540µmol/L; 4)18 to 65 years old male or female; (5) no drugs that could affect the observation of the study were used in the 15 days before enrollment; 6) Consent to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) History of acute gout attack renal calculi tophi formation uric acid nephropathy and other complications; 2) Suspicious secondary hyperuricemia such as blood disease kidney disease tumor radiotherapy and chemotherapy or taking related drugs Viremia; 3) patients with severe heart liver and kidney diseases; 4) pregnant or lactating patients; 5) drug contraindications and allergies; 6) participated in other clinical trials in the last 3 months.

Design outcomes

Primary

MeasureTime frame
Blood uric acid control rate;

Secondary

MeasureTime frame
The fluctuation of blood uric acid;The average dosage of allopurinol tablets; Chinese medicine symptom complex score;The time of the first acute gout attack;Conversion rate of gout;The number of gout attacks;

Countries

China

Contacts

Public ContactWang Weijia

The Third People's Hospital affiliated to Fujian University of Traditional Chinese Medicine

879500118@qq.com13696838265

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026